Rapid clinical improvement can also be achieved via neonatal Fc receptor (FcRn) blockade—for example efgartigimod and rozanolixizumab—with randomized trials demonstrating early benefits in generalized MG cohorts (42, 43). Here, FCGRT is linked to myasthenia gravis.